Previous 10 | Next 10 |
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting - LP-284 demonstrated distinct anti-tumor activity in hematologic cancer cells - LP-284 exhibited potency in lymphoma, ...
Lantern Pharma (NASDAQ:LTRN) has announced a share repurchase program to buyback up to $7M of its common stock. As of October 29, 2021, Lantern Pharma had ~11.2M shares of common stock outstanding. Panna Sharma, CEO and President of Lantern Pharma, said "Initiating a share repurchase program ...
Lantern Pharma Announces Share Repurchase Program PR Newswire DALLAS , Nov. 22, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), a clinical stage biopharmaceutical company using its proprietary RADR ® artifi...
Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...
Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day PR Newswire DALLAS , Nov. 12, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical sta...
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting PR Newswire DALLAS , Nov. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage b...
Lantern Pharma to Participate in Two Upcoming Investor Conferences PR Newswire DALLAS , Nov. 9, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A....
Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting PR Newswire DALLAS , Nov. 4, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinic...
Lantern Pharma Inc. (LTRN) Q3 2021 Earnings Conference Call November 1, 2021 16:30 ET Company Participants Nicole Leber - Finance & Administrative Coordinator Panna Sharma - President, Chief Executive Officer & Director David Margrave - Chief Financial Officer & Secretary Kishor B...
Lantern Pharma (NASDAQ:LTRN): Q3 GAAP EPS of -$0.36 misses by $0.09. Press Release For further details see: Lantern Pharma EPS misses by $0.09
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...